UPDATED: Top gene therapy deals, M&A pacts in 2020 highlight another big year in one of the hottest fields in biopharma
(Editor’s note: We got a few emails after this piece was published, raising some questions about how we classified different deals. Chris Dokomajilar — who’s a stickler about getting things right — reevaluated the information and revised his charts. He also helpfully added a lot more detail on gene editing, which we’ve included below, and how those deals have stacked up alongside gene therapy. If you have any other questions or suggestions, drop me a line. — John Carroll)
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 109,800+ biopharma pros reading Endpoints daily — and it's free.